Related Experiment Video
Updated: Jun 22, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Building a protocol expressway: the case of Mayo Clinic Cancer Center
Terre A McJoynt1, Muhanad A Hirzallah, Daniel V Satele
1Cancer Center Clinical Research Office, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. mcjoynt.terre@mayo.edu
Purpose:
Inconsistencies and errors resulting from nonstandard processes, together with redundancies, rework, and excess workload, lead to extended time frames for clinical trial protocol development. This results in dissatisfaction among sponsors, investigators, and staff and restricts the availability of novel treatment options for patients.
Methods:
A team of experts from Mayo Clinic formed, including Protocol Development Unit staff and management from the three Mayo Clinic campuses (Florida, Minnesota, and Arizona), a systems and procedures analyst, a quality office analyst, and two physician members to address the identified deficiencies. The current-state process was intensively reviewed, and improvement steps were taken to accelerate the development and approval of cancer-related clinical trials. The primary goal was to decrease the time from receipt of a new protocol through submission to an approving authority, such as the National Cancer Institute or institutional review board.
Results:
Using the Define, Measure, Analyze, Improve, Control (DMAIC) framework infused with Lean waste-reduction methodologies, areas were identified for improvement, including enhancing first-time quality and processing new studies on a first-in/first-out basis. The project was successful in improving the mean turnaround time for internally authored protocols (P < .001) from 25.00 weeks (n = 41; range, 3.43 to 94.14 weeks) to 10.15 weeks (n = 14; range, 4.00 to 22.14 weeks). The mean turnaround time for externally authored protocols was improved (P < .001) from 20.61 weeks (n = 85; range, 3.29 to 108.57 weeks) to 7.79 weeks (n = 50; range, 2.00 to 20.86 weeks).
Conclusion:
DMAIC framework combined with Lean methodologies is an effective tool to structure the definition, planning, analysis, and implementation of significant process changes.
Insights
Streamlining clinical trial protocol development using the Define, Measure, Analyze, Improve, Control (DMAIC) framework and Lean methodologies significantly reduced turnaround times for both internal and external protocols, accelerating patient access to new treatments.
Area of Science:
- Clinical research operations
- Process improvement methodologies
- Healthcare systems engineering
Background:
- Nonstandard processes in clinical trial protocol development lead to delays, errors, and increased workload.
- These inefficiencies result in sponsor dissatisfaction and limit patient access to novel therapies.
Purpose of the Study:
- To improve the efficiency and reduce the turnaround time of clinical trial protocol development.
- To address inconsistencies, redundancies, and rework in the protocol development process.
Main Methods:
- A multidisciplinary team at Mayo Clinic was assembled to review and optimize the protocol development process.
- The Define, Measure, Analyze, Improve, Control (DMAIC) framework was integrated with Lean waste-reduction principles.
- Improvements focused on enhancing first-time quality and implementing a first-in/first-out workflow.
Main Results:
- Mean turnaround time for internally authored protocols decreased from 25.00 to 10.15 weeks (P < .001).
- Mean turnaround time for externally authored protocols decreased from 20.61 to 7.79 weeks (P < .001).
- The implemented changes significantly improved process efficiency and reduced delays.
Conclusions:
- The DMAIC framework, combined with Lean methodologies, provides an effective structure for implementing substantial process improvements.
- This approach successfully reduced clinical trial protocol development timelines, benefiting all stakeholders and patients.
Related Concept Videos
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic illness...
Hospitals-II
Nurses that work in hospitals have...
Coronary Artery Disease V: Interprofessional Care
Clinical Trials
There are four phases in a clinical trial. A phase one...
Patient-centered Care
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

